||NewLink Genetics Corporation
||United States District Court for the Southern District of New York
||The Hon. William H. Pauley III
||Between September 17, 2013 and May 9, 2016
On May 12, 2016, the initial complaint in this securities class action was filed against NewLink Genetics Corporation (“NewLink” or the “Company”), and certain of NewLink’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. The Complaint alleges that throughout the class period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients; and (ii) as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
On July 31, 2018, defendants filed a Motion to Dismiss the Second Amended Complaint. On February 13, 2019, the Court issued an Order granting defendants' Motion to Dismiss. On March 14, 2019, Lead Plaintiffs appealed that decision to the United States Court of Appeals for the Second Circuit. On July 13, 2020, the Second Circuit affirmed in part and reversed in part the District Court's dismissal Order, and the case was remanded back to the District Court for further proceedings.
This action is still ongoing. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at firstname.lastname@example.org